• Home
  • About Us
    • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Management Team
    • Careers
  • For Researchers
    • Paxalisib
    • EVT801
    • Collaborating with Kazia
    • Publications and Presentations
  • For Partners
    • Our Current Partners
    • What We Are Looking For
  • For Patients
    • Accessing Kazia Drug Candidates in Clinical Trials
    • Accessing Kazia Drug Candidates for Compassionate Use
    • Resources for Patients
  • For Investors
    • Press Releases
    • ASX Announcements
    • Delisting from ASX
      • How to convert unlisted shares to ADSs
    • SEC Filings
    • Corporate Presentations
    • Annual Reports
    • Financial Reports
    • AGM
    • Corporate Governance
    • Shareholder Services
  • Media Centre
    • Overview
    • Video
    • Coverage
  • Contact
    • Contact Us
    • Subscribe to email alerts
Kazia Therapeutics Limited
Home / Media Centre / Coverage
  • Overview
  • Video
  • Coverage

Recent Posts

  • Kazia Therapeutics says diversification is the key to drug development
  • Kazia Therapeutics’ oncology drug paxalisib continues to generate positive trial data
  • Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference
  • Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer
  • Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer

Archives

  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • February 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • July 2021
  • April 2021
  • February 2021
  • December 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020

Categories

  • GENERAL
  • MEDIA RELEASE
  • Uncategorized

Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer

Posted in Uncategorized

In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022.

Read More

 

Quick Links

Contact Us

Kazia Therapeutics Limited
Three International Towers
Level 24, 300 Barangaroo Avenue
Sydney NSW 2000, Australia

info@kaziatherapeutics.com
https://www.kaziatherapeutics.com

Subscribe to Email Alerts

Which of the following group do you best fit?

 

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Kazia Therapeutics Limited
Site Map Privacy Search
Design byspatialdesign Site by